Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Invivyd (IVVD) said the FDA issued a Notice of Termination for the PEMGARDA (pemivibart) COVID-19 Emergency Use Authorization, with EUA termination set for June 29, 2027. The action follows HHS’s advanced termination notice for the COVID-19 EUA declaration, effective June 29, 2027. While the product remains an investigational monoclonal antibody authorized for pre-exposure prophylaxis since March 2024, the planned EUA wind-down is a clear near-to-medium term commercial headwind.

Analysis

This is negative less because revenue stops tomorrow than because it hard-codes a terminal date onto a product that likely already carried a high regulatory discount. For a small biotech, that shifts the market from valuing a growth bridge to valuing a wasting asset: even if near-term demand holds, the multiple should compress as investors mark down the option value of the franchise and the probability of future dilution rises.

The key second-order effect is capital markets access. If management had been relying on PEMGARDA to fund pipeline optionality, the financing window just tightened; any rally tied to near-term sales could be sold into via ATM or follow-on. In the broader COVID prophylaxis space, this reinforces a structural preference for assets with full approvals or non-EUA pathways, while EUA-dependent programs elsewhere in biotech may see the bar for funding move higher.

Timing matters: the first move is likely a headline-driven selloff, but the more durable pressure comes over 1-3 months as investors focus on run-rate sales, gross margin, and cash burn. The thesis is falsified if IVVD shows a credible path to an approved successor asset, a partnership that de-risks commercialization, or materially better-than-expected cash runway that removes dilution risk.

Contrarian view: the market may overreact because the termination date is still far out, so this is not an immediate revenue cliff. If the stock has already been heavily discounted, the cleaner trade is to fade any relief rally rather than press size on the first print.

Key Decisions for Investors

• Short IVVD on any post-news bounce over the next 1-5 trading days; use a tight stop if the stock reclaims the pre-announcement gap, since the near-term move may be mechanically overdone.
• If liquidity allows, buy 1-3 month IVVD puts rather than outright short stock to capture the regulatory overhang with defined risk; the thesis is strongest if implied vol has not fully repriced the event.
• Watch for an ATM or follow-on filing over the next 30-90 days; that would confirm the market’s weakest point is financing, not just sentiment, and would be a secondary short entry.
• Pair trade: short IVVD vs. long XBI for the next 1-3 months to isolate company-specific regulatory decay from broader biotech beta.
• Cover part of the short if management announces an approved replacement pathway or partner-backed transition plan; that would invalidate the "melting ice cube" framing.